Company founded in 2010, Ann Arbor, Michigan.
Developer of metabolic profiling technologies designed to automate the measurement of biochemicals in biological systems. Patented protocols embed chemical signatures into complex internal standards which are readily easily identified in mass spectral data using software algorithms. These complex internal standards can be spiked into biological samples, i.e. blood, urine, biopsies etc. to identify and quantitate 100s of metabolites. Key is that these protocols remove mass spectral ionization inefficiencies/matrix effects which is the leading cause of unreproducible data. The result is suppression-corrected data, complete cross-platform quantitative reproducibility, with validated compound identification. Better data translates into biomarkers for diseases, diagnostics and drug development.
Chris Beecher, Founder and Chief Scientific Officer
Chris has more than 25 years of experience in metabolomics, drug discovery and development, and holds 12 patents and 75 publications. His Ph.D. was awarded in Pharmaceutical Sciences (specialty, Natural Products Chemistry and Biochemistry) from the University of Connecticut in 1986. Dr. Beecher served as Director for Drug Development with Ancile Pharmaceuticals and Associate Director for Natural Products Drug Discovery for Bristol-Myers Squibb (BMS). Before joining BMS, Chris was a tenured Associate Professor in the Department of Medicinal Chemistry and Pharmacognosy in the College of Pharmacy at the University of Illinois at Chicago.
Chris is a metabolomic platform development pioneer. In 2001, Dr. Beecher was appointed as the Director of Metabolic Profiling at Paradigm Genetics, Inc. where he was responsible for building the world’s first parallel metabolomics platform. He later became the sole technical founder of Metabolon, Inc. where he continued to build metabolomics platforms and work in discovery. Following the discovery of the metabolite biomarker sarcosine in prostate cancer, Dr. Beecher became a Professor in the Department of Pathology, at the Medical School of the University of Michigan and assumed the position of Director of the UM Metabolomics Facility. Chris is currently Chief Scientific Officer for IROA Technologies where he oversees the continuous development of next generation metabolomics, data generation and data interpretation platforms.
Felice A. de Jong, Founder and Chief Executive Officer
Felice has an extensive and distinguished career in metabolomics, and life science. She holds post-graduate degrees in Technology Management from Macquarie University, Sydney, Australia; Nutritional Biochemistry from the University of Connecticut; and a doctorate in Molecular Biology and Biochemistry from the University of Melbourne, Australia.
Dr. de Jong was Technical Manager, Biochemistry at Boehringer Mannheim (Roche), Australia and the founding President of Sigma Aldrich Australia, developing her first company to a successful venture from the ground up. Dr. de Jong returned to Sigma-Aldrich in Boston, USA where she ran Sigma’s neurobiology subsidiary, RBI, as its President.
Felice has been an active leader and proponent in the field of metabolomics since its emergence. She developed metabolomics business and marketing strategies during her 6 years as Senior/ Director of Business Development for Metabolon. Her current focus at IROA Technologies is to develop services and products that remove bottlenecks to streamline the measurement of biological response to stressors such as disease, adverse environmental conditions, drugs, and toxins.